OptiNose Appoints Keith Goldan as Chief Financial Officer
OptiNose Appoints Keith Goldan as Chief Financial Officer
Goldan adds extensive biopharma finance and operational experience
YARDLEY, PA, January 26, 2017 – OptiNose today announced the appointment of Keith A. Goldan as Chief Financial Officer (CFO). Mr. Goldan brings to the company more than 25 years of executive finance and operational leadership in biopharmaceutical and medical technology companies. He will be responsible for the financial leadership of the company, including investor relations, working to ensure the Company is properly capitalized with established controls for financial reporting.
"With Keith's appointment, we continue to solidify our leadership team with experienced biopharma executives able to transition the company from development to commercial stage," said Peter Miller, Chief Executive Officer of OptiNose. "Keith has an exemplary track record of financial leadership and value creation for companies of all sizes, and he will be critical to our efforts to ensure we are appropriately capitalized as we build OptiNose into a leading ENT / Allergy specialty company."
Goldan is an experienced CFO of private and public biopharma companies from early stage through commercial stage, including Fibrocell, NuPathe, PuriCore (now Realm Therapeutics) and Biosyn. During his career, he successfully raised more than $250 million in multiple Initial Public Offerings as well as follow-on equity, rights, private placement and debt offerings and has led multiple M&A transactions, including NuPathe's sale to Teva in 2014 and Biosyn's sale to Cellegy in 2004. Goldan's experience also includes a variety of roles with ViroPharma; Century Capital Associates, a specialty consulting firm with a focus on capital strategy for healthcare clients; and the Healthcare & Life Sciences Practice of KPMG.
"OptiNose is at a pivotal stage in its evolution as it prepares for the commercialization of OPN-375," said Goldan. "I am excited and honored to join this outstanding team. OPN-375 has the potential to help millions of chronically suffering patients, and I look forward to working hard to create long-term value for them and all of our stakeholders."
Mr. Goldan holds a BS (cum laude) in finance from the Robert H. Smith School of Business at the University of Maryland and an MBA from the Wharton School of Business at the University of Pennsylvania.
About OptiNose
OptiNose is a commercial stage ENT / Allergy Specialty Biopharmaceutical Company on a mission to improve lives. The Company's first technology platform involves a patented closed-palate Breath Powered® technology used to develop Exhalation Delivery Systems that produce high and deep intranasal deposition of medication. These exhalation delivery systems enable creation of products with the potential for meaningful new clinical benefits. OptiNose developed and out-licensed its first product at the end of Phase 3 (Onzetra™ Xsail™ (sumatriptan nasal powder), licensed to Avanir in North America, since acquired by Otsuka Pharmaceutical Co., Ltd.). Onzetra Xsail received FDA approval in January 2016 and was launched in the U.S. in May 2016. The Company's second product candidate, an Exhalation Delivery System with fluticasone propionate (OPN-375) is being developed for treatment of nasal polyposis and chronic sinusitis. An NDA seeking marketing approval for the treatment of nasal polyposis was submitted in November 2016. Subsequent OptiNose pipeline products will aim to serve the needs of patients treated by ENT and allergy specialists. The Company also is engaged in early development work on products for neurologic orphan diseases where the "nose-to-brain" application of its technology may enable improved treatment. This includes OPN-300 (Prader-Willi Syndrome, Autism, others) and OPN-21 (narcolepsy and others). OptiNose has corporate offices in the US, UK and Norway.
OptiNose Media Contact
Kate Traynor, Sloane & Company
Ktraynor@sloanepr.com
212.446.1871
